These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28342067)

  • 1. The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation.
    Lichtenberg S; Rahamimov R; Green H; Fox BD; Mor E; Gafter U; Chagnac A; Rozen-Zvi B
    Eur J Clin Pharmacol; 2017 Jul; 73(7):819-826. PubMed ID: 28342067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus Levels Are Not Associated with Risk of Malignancy in Lung Transplant Recipients.
    Fox BD; Ashquar F; Raviv Y; Rozengarten D; Straichman O; Izhakian S; Kramer MR
    Ann Transplant; 2017 Nov; 22():677-681. PubMed ID: 29133776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
    Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
    Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined introduction of anti-IL2 receptor antibodies, mycophenolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective cohort study.
    Braconnier P; Del Marmol V; Broeders N; Kianda M; Massart A; Lemy A; Ghisdal L; Le Moine A; Madhoun P; Racapé J; Abramowicz D; Wissing KM
    Nephrol Dial Transplant; 2012 Jun; 27(6):2547-53. PubMed ID: 22123748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V; Tchervenkov J; Metrakos P; Barkun J; Deschenes M; Cantarovich M
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Tacrolimus Trough Level in Patients Who Developed Post-transplant Diabetes Mellitus After Kidney Transplantation: A Retrospective Single-Center Study in Saudi Arabia.
    Ajabnoor A; Nasser M; Khan N; Habhab W
    Transplant Proc; 2020 Dec; 52(10):3160-3167. PubMed ID: 32636070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients.
    Chen YH; Zheng KL; Chen LZ; Dai YP; Fei JG; Qiu J; Li J
    Transplant Proc; 2005 Dec; 37(10):4246-50. PubMed ID: 16387090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Average Tacrolimus Trough Level in the First Month After Transplantation May Predict Acute Rejection.
    Aktürk S; Erdoğmuş Ş; Kumru G; Elhan AH; Şengül Ş; Tüzüner A; Keven K
    Transplant Proc; 2017 Apr; 49(3):430-435. PubMed ID: 28340806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
    Hakeam HA; Al-Jedai AH; Raza SM; Hamawi K
    Ann Transplant; 2008; 13(2):46-53. PubMed ID: 18566560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation.
    Rozen-Zvi B; Schneider S; Lichtenberg S; Green H; Cohen O; Gafter U; Chagnac A; Mor E; Rahamimov R
    Nephrol Dial Transplant; 2017 Feb; 32(2):393-399. PubMed ID: 28025383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus.
    Rodrigo E; de Cos MA; Fernández-Fresnedo G; Sánchez B; Ruiz JC; Piñera C; Palomar R; Cotorruelo JG; Gómez-Alamillo C; de Castro SS; de Francisco AL; Arias M
    Transplant Proc; 2005 Nov; 37(9):3819-20. PubMed ID: 16386549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
    González-Roncero FM; Gentil-Govantes MÁ; González-Molina M; Rivero M; Cantarell C; Alarcón A; Franco A; Sánchez-Plumed J; Lampreabe I; Lauzurica R; González E; Romero R; Ruiz-San Millán JC; Osuna A
    Nefrologia; 2012 Jul; 32(4):446-54. PubMed ID: 22806279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation.
    Barone GW; Ketel BL; Abul-Ezz SR; Lightfoot ML
    JOP; 2002 Mar; 3(2):49-53. PubMed ID: 11884766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intervention of Online Percent Coefficient of Variation Reporting System Reduces the Variability of Tacrolimus Trough Concentration in Kidney Transplant Recipients.
    Cheng CY; Wu MJ; Lin CC; Hou YC; Liou WS
    Transplant Proc; 2018 Oct; 50(8):2401-2403. PubMed ID: 30316366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus.
    Borrows R; Chusney G; Loucaidou M; James A; Stichbury J; Van Tromp J; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D
    Ther Drug Monit; 2006 Apr; 28(2):269-73. PubMed ID: 16628143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.